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1. Introduction 
Platelet-activating factor (PAF), a mediator of 
anaphylaxis and inflammation, is released from 
IgE-sensitized antigen-stimulated basophils [l-3]. 
PAF is a low molecular weight phospholipid which 
is sensitive to hydrolysis by phospholipases AZ, C, 
and D, but not by lipase from Rhizopus arrhizus 
or sphingomyelinase C [4]. PAF appeared to be a 
glycerophospholipid with a choline polar head group 
devoid of an ester function at position 1 [4,5]. The 
presence of PAF has been demonstrated in cells 
from several species including man [3,6,7], rabbit 
[l-3], rat [8] and pig [4]. PAF has been obtained 
from rat and mouse peritoneal macrophages upon 
stimulation by the ionophore A23187 or exposure 
to phagocytable particles [9]. PAF has been shown 
to induce aggregation of blood platelets from rabbit 
[1,3],man [lO],rat [ll] andguineapig [12].The 
structure of the molecule responsible for PAF activity 
has been elucidated [13,14]. This was obtained by 
acetylation of 2-lyso plasmalogens possessing a 
30phosphoryl choline group [ 131 or a 3-O-phos- 
phoryl ethanolamine group followed by reaction with 
diazomethane and quaternization with methyl iodide 
[ 141. This result lead us to propose a 1 -O-alkyl 
2-0-acetyl sn-glycero3-phosphoryl choline structure 
and the terminology ‘PAF-acether’ for this substance. 
However, total synthesis was necessary to confirm 
the structure of PAF-acether. Here, we report the 
total synthesis of l-O-octadecyl20acetyl sn-glycero- 
3-phosphoryl choline, which has the same biological 
activity as the natural PAF-acether. 
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2. Materials and methods 
2.1. Chemistry 
Solvents were all reagent grade. Column chroma- 
tographs were prepared with Silica gel 40 or 60 
from Merck, without any special treatment unless 
otherwise specified. Melting points were determined 
on a Biichi capillary melting point apparatus and were 
uncorrected. Optical rotation values were measured 
at room temperature in a 5 mm tube using a Roussel- 
Jouan polarimeter. The purity of each compound was 
controlled by thin-layer chromatography on silica gel. 
Infrared spectra were recorded on a PYE UNICAM 
SP3-200 and NMR spectra were obtained using either 
a Varian EM 360 or a Varian T 60 spectrometer in 
CDCls with TMS as an internal standard. Elemental 
analysis were performed by the Laboratoire de 
Microanalysis, University of Paris VII and the Institut 
de Chimie des Substances Naturelles (ICSN), Centre 
National de la Recherche Scientifique (CNRS), 
Gif s/Yvette. 
2.2. Biological assay 
PAF-acether activity was determined in an aggre- 
gometer apparatus (Icare, Marseille) by aggregation 
of 5 X lo* washed rabbit platelets in 300 fl Tyrode’s 
buffer in the presence of 5 @I indomethacin (Sigma 
Chemicals, St Louis, MO). It was expressed in arbi- 
trary units as measured by the relative chart distance 
for the aggregation produced by 10 ~1 PAF-acether 
containing solution. Preparation of platelets, com- 
position of buffers and assay of PAF-acether have 
been detailed in [4,5,9]. 
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3. Results 
3.1. Synthesis 
The 1-O-octadecyl sn-glycerol J_ (scheme l), pre- 
pared in eight steps from D-mannitol by the methods 
in [ 1 S-171, and adapted to our use, was converted 
into the 1 0octadecyl30trityl sn-glycerol 2. as 
proved by IR spectra: 3080,3040,1600 cm-’ for 
the trityl group and NMR spectra: 6 ppm 7.26 (mul- 
tiplet, 15H, aromatic H) (see table 1). The 2 deriva- 
tive was acetylated to yield the 1 Ooctadecyl 
2-0acetyl3Gtrityl sn-glycerol3: IR, 1735 cm-’ 
for v C=O; NMR, 6 ppm 2.00 (singlet, 3H, CH,CO), 
5.16 (quintuplet-like, J = 6 Hz, lH, CH. After reduc- 
tion by Hz on charcoal/Pd, 2 gave the 1-U-octadecyl 
FEBS LETTERS July 1980 
20acetyl sn-glycerol A: IR, 3450 cm-’ v OH, 
1735 cm-’ v GO; NMR, 6 ppm 4.93 (quintuplet-like, 
J = 6 Hz, lH, CH), proof that the acetyl group was 
retained in the 2-position. 3 was then treated by 
2-bromoethylphosphoryl dichloride in dry ether by 
the method in [ 181 simplified. After hydrolysis and 
chromatography, the 1 -O-octadecyl20acetyl 
sn-glycero-3-phosphoryl2’-bromoethanol5 was 
obtained as shown by NMR spectra and elemental 
analysis. 5 was treated by an excess of trimethyl- 
amine according to [ 191 and by silver carbonate to 
give the 1 -O-octadecyl2-0-acetyl sn-glycero3-phos- 
phoryl choline 6. The NMR signal for (CH&N’ 
appeared at 3.36 ppm as a broad singlet (9H) and the 
elemental analysis was in significant agreement with 
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Table 1 
Physicochemical results 
Compound 
no. 
Purification Yield m.p. 
(%) (“C) 
[o] &2*sa Silica gel TLC Analyses 
RF (development) 
Calc. Found 
1 recryst. (hexane) 71b -0.86” 0.10’ (iodine) C: 73.25 72.91 _ 
H: 12.79 12.85 
2 Silica gel 40 99.5 55 +1.08” 0.60’ C: 81.86 82.01 _ 
column d H: 9.89 10.08 
3 Silica gel 60 81 44 +8.90” 0.80c C: 80.25 80.33 _ 
columnd H: 9.55 9.59 
4 Silica gel 60 Surfused Not measured 0.24’ (iodine) C: 71.51 71.46 - 
column deactivatede H: 11.91 11.91 
5 Silica gel 60 61 46 -3.05” 0.848 (molyb- C: 52.35 51.81 
- columnf denum sprayh) H: 8.12 8.80 
Br: 13.96 13.10 
6 Silica gel 6() 59 Decomposition -3.38’ O.OOg (molyb- C: 60.98 61.39 _ 
column’ from 200°C denum sprayh) H: 10.53 10.64.. 
N: 2.54 2.6Or 
P: 5.63 6.01i 
a Cont., 1 gin 100 ml CHCl,; b Lit., 71-72°C [20]; ’ Ether-light petroleum (b.p. 30-60°C) 30:70 (v/v); d Ether-light petro- 
leum (b.p. 30-60°C) 15:85 (v/v); e Ether-light petroleum (b.p. 30-60°C) 30:70 (v/v); f Solvent system in increasing order of 
polarity: chloroform, chloroform-methanol (85:15, v/v), chloroform-methanol (70:30, v/v) and chloroform-methanol (50:50, 
v/v); g Chloroform-methanol (70:30, v/v); h See [Zl]; 1 Solvent system in gradually increasing order of polarity: chloroform- 
methanol (70:30, v/v) to chloroform-methanol (30:70, v/v) and methanol alone; i N/P = 0.96 
calculated values. The chemical ionization mass 
spectrum using isobutane as reactant gas showed 
the MH’ peak m/e 552 [5,20]. Although the treat- 
ment with silver carbonate in order to obtain the 
internal salt exhibited a slight deacetylation into a 
lyso-derivative as observed by high pressure liquid 
chromatography. Other methods of synthesis will be 
described elsewhere. 
3.2. Characterization of natural and synthetic 
PAF-acether 
Several criteria were used to verify that the syn- 
thetic compound 6 exhibited the same biological 
characteristics as that of natural PAF-acether: aggre- 
gation of platelets by natural or synthetic PAF- 
acether 6 was not influenced by indomethacin. 
PAF-acether 6 containing solution was completely 
inactivated after incubation for 10 min at 37°C with 
phospholipase AZ (Boehringer, Mannheim). Natural 
and synthetic PAF-acether 6 migrated on silicic acid 
thin-layer chromatography between sphingomyelin 
and lysophosphatidylcholine, with an RF 0.35 and 
exhibited identical retention time on silicic acid 
high pressure liquid chromatography [5]. Synthetic 
PAF-acether 6 exhibited spec. act. 13 units/rig (arbi- 
trary units as defined in section 2.2.) as compared 
to 6 units/rig for the semi-synthetic PAF-acether. 
It was difficult to assess pecific activity of natural 
PAF, given the lack of ponderous material. However, 
it was approximately between the semi-synthetic and 
the synthetic substances. 
4. Discussion 
These data demonstrate clearly that we succeeded 
in synthetizing a compound the structure of which 
corresponded to that of PAF-acether. The synthetic 
compound 6 met with the biological and physico- 
chemical criteria used for characterization of natural 
PAF-acether. Moreover, none of the intermediate 
compounds exhibited any platelet-aggregating activity 
observed only when full synthesis was completed, 
indicating specificity of the structure exhibited by 
this compound. Preliminary studies have shown that 
the 2-O-propionyl and the 2Gbutyryl derivatives 
were much less active than the 2-O-acetyl compound 
in inducing platelet aggregation (in preparation). 
However, if this study shows clearly that the specific 
activity of the 10octadecyl compound is very high, 
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as compared to the semi-synthetic substance obtained 
from natural plasmalogens, there still remains uncer- 
tainty on possible variations in length of the 1 Oalkyl 
chain. 
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